Sugi Predict

Sugi Predict / Targets / CCNT1

CCNT1

Cyclin-T1 · O60563 · CCNT1 on Sugi Atlas →

160,122 patent compounds predicted against CCNT1, 89,606 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL268925 SCHEMBL268925 0.50 17/20
SCHEMBL269583 SCHEMBL269583 0.50 17/20
SCHEMBL102235 SCHEMBL102235 1.00 13/20
SCHEMBL102955 SCHEMBL102955 1.00 13/20
SCHEMBL102656 SCHEMBL102656 0.79 13/20
SCHEMBL102951 SCHEMBL102951 0.76 13/20
SCHEMBL102660 SCHEMBL102660 0.75 13/20
SCHEMBL370555 SCHEMBL370555 0.42 13/20
SCHEMBL370556 SCHEMBL370556 0.42 13/20
SCHEMBL102233 SCHEMBL102233 1.00 12/20
SCHEMBL103266 SCHEMBL103266 0.79 12/20
SCHEMBL102507 SCHEMBL102507 0.78 12/20
SCHEMBL102650 SCHEMBL102650 0.76 12/20
SCHEMBL103265 SCHEMBL103265 1.00 11/20
SCHEMBL102984 SCHEMBL102984 0.77 11/20
SCHEMBL102952 SCHEMBL102952 0.76 11/20
SCHEMBL517413 SCHEMBL517413 0.54 11/20
SCHEMBL368357 SCHEMBL368357 0.40 11/20
SCHEMBL368358 SCHEMBL368358 0.40 11/20
SCHEMBL368359 SCHEMBL368359 0.40 11/20

Clinical trials — most relevant to CCNT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
A Study of Abemaciclib in Recurrent Glioblastoma PHASE2ACTIVE_NOT_RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer nanNOT_YET_RECRUITING
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNT1 binder may also engage these)

ProteinNameSimilarity
Q8HXN7 — 1.000 Q8HXN7 →
Q9QWV9 — 1.000 Q9QWV9 →
Q9XT26 — 1.000 Q9XT26 →
CCNT2 Cyclin-T2 1.000 landscape →
Q6T8E9 — 1.000 Q6T8E9 →
Q7TQK0 — 0.999 Q7TQK0 →
Q8K0V4 — 0.997 Q8K0V4 →
Q5HZJ0 — 0.997 Q5HZJ0 →
Q8BYH8 — 0.997 Q8BYH8 →
Q80TZ9 — 0.997 Q80TZ9 →
Q52LR7 — 0.997 Q52LR7 →
KAT6B Histone acetyltransferase KAT6B 0.996 landscape →
Q90YL3 — 0.996 Q90YL3 →
P01103 — 0.996 P01103 →
P83038 — 0.996 P83038 →
Q3UTQ8 — 0.996 Q3UTQ8 →
E1C2V1 — 0.996 E1C2V1 →
Q9FNY0 — 0.996 Q9FNY0 →
A7MBB4 — 0.996 A7MBB4 →
P46200 — 0.996 P46200 →
Q9N1U3 — 0.996 Q9N1U3 →
Q5RBA1 — 0.996 Q5RBA1 →
Q9CWL2 — 0.996 Q9CWL2 →
Q92539 — 0.995 Q92539 →
Q9ULH7 — 0.995 Q9ULH7 →
Q9LXV4 — 0.995 Q9LXV4 →
A6ZZY3 — 0.995 A6ZZY3 →
Q9Z1N7 — 0.995 Q9Z1N7 →
P35680 — 0.995 P35680 →
P27889 — 0.995 P27889 →